Nisa Investment Advisors’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Nisa Investment Advisors’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-562	Closed	-$1K	–	2913
2023 Q1	$1K	Hold	562	–	–	﹤0.01%	2506
2022 Q4	$1K	Buy	+562	New	+$800	﹤0.01%	2560
2022 Q3	–	Sell	-660	Closed	-$2K	–	2656
2022 Q2	$2K	Hold	660	–	–	﹤0.01%	2353
2022 Q1	$4K	Hold	660	–	–	﹤0.01%	2328
2021 Q4	$5K	Hold	660	–	–	﹤0.01%	2100
2021 Q3	$5	Hold	660	–	–	﹤0.01%	2263
2021 Q2	$4	Hold	660	–	–	﹤0.01%	2287
2021 Q1	$7	Hold	660	–	–	﹤0.01%	2246
2020 Q4	$5K	Sell	660 -500	-43%	-$3.89K	﹤0.01%	2269
2020 Q3	$9K	Buy	1,160 +660	+132%	+$4.09K	﹤0.01%	2143
2020 Q2	$3K	Hold	500	–	–	﹤0.01%	2044
2020 Q1	$2K	Buy	+500	New	+$2.88K	﹤0.01%	2052

Other funds holding JNCE

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Nisa Investment Advisors's JNCE Position: Q2 2023 in Review

Nisa Investment Advisors sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 562 shares — an estimated $1K sold.

Nisa Investment Advisors first reported a position in JNCE in Q1 2020 and held it in 12 quarters. The position peaked at $9K in Q3 2020. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

Nisa Investment Advisors reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Nisa Investment Advisors sold 562 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $1K.
Nisa Investment Advisors first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2020 and held it in 12 quarters.
Nisa Investment Advisors's Jounce Therapeutics, Inc. Common Stock position peaked at $9K in Q3 2020.
1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Nisa Investment Advisors's 13F filing for Q2 2023, filed 11 Aug 2023.